Skip to main content
Premium Trial:

Request an Annual Quote

ChromaCode Partners With Medical College of Georgia on Non-Small Cell Lung Cancer Rapid PCR Testing

NEW YORK – ChromaCode said Wednesday that it has partnered with the Medical College of Georgia's department of pathology to test the analytical and clinical performance of ChromaCode's PCR-based non-small cell lung cancer biomarker assay.

Financial terms of the partnership were not disclosed.

The test utilizes ChromaCode's high-definition PCR (HDPCR) technology, which involves machine learning algorithms and novel chemistries that increase the multiplexing capabilities of standard lab instruments. The panel covers all variants identified by the National Comprehensive Cancer Network as clinically relevant in NSCLC with a four-hour workflow for rapid results.

ChromaCode cited recently published research in the journal Diagnostics, which demonstrated high sensitivity for the assay even with minimal input material. The test detected SNPs, insertions, and deletions, as well as RNA fusions, with high concordance to other methods including next-generation sequencing.

With the Medical College of Georgia, the company plans to continue the validation process to more definitively establish the analytical and clinical performance of the NSCLC kit.

"Given results to date for the NSCLC HDPCR assay in terms of speed and accuracy, we believe that it has the potential to reduce turnaround times and in the future benefit patients with specific mutations for which there are targeted treatment options," Ravindra Kolhe, professor and interim chair of the department of pathology at the Medical College of Georgia at Augusta University, said in a statement.